Omthera Looks To Take Lead In Omega-3 Space, Armed With Data Showing Advantages Over Lovaza
This article was originally published in The Pink Sheet Daily
Privately held New Jersey firm expects data from pivotal Phase III trial of Epanova during first half of 2012, with NDA to follow shortly.
You may also be interested in...
FDA leaves door open to modify label of Amarin’s omega-3 fatty acid therapy Vascepa prior to approval in a healthier population, says company CEO. Per the current label, triglycerides are lowered significantly with no increase in LDL cholesterol, a potential differentiating point from Pronova/Glaxo’s blockbuster EPA/DHA therapy Lovaza.
A second set of clinical trial results expands the potential market for AMR101 tenfold, triggering increased investor and partnership interest.
Feisty Amarin is certainly undergoing a reincarnation.